Jpn. J. Pharmacol. 83 (2), 107-112 (2000)


Electrophysiological and Cardiohemodynamic Effects of AH-1058, a New Type Calcium Channel Blocker, Assessed by the In Vivo Canine Model

Akira Takahara1, Atsushi Sugiyama2,*, Hideki Dohmoto1, Ryota Yoshimoto1 and Keitaro Hashimoto2


1Pharmaceutical╩Research Laboratories, Ajinomoto Co., Inc., 1-1 Suzuki-cho, Kawasaki-ku, Kawasaki 210-8681, Japan
2Department╩of Pharmacology, Yamanashi Medical University, Tamaho-cho, Nakakoma-gun, Yamanashi 409-3898, Japan
*╩To whom correspondence should be addressed.

Abstract: AH-1058╩(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-[(E)-3-(3-methoxy-2-nitro)phenyl-2-propenyl]piperidine hydrochloride) is a novel calcium channel blocker whose chemical structure is quite different from those of typical calcium channel blockers. In this study, electrophysiological and hemodynamic effects of AH-1058 were assessed in the halothane-anesthetized, closed-chest canine model. Intravenous administration of a canine antiarrhythmic dose of 100╩mg/kg of AH-1058 (n=6) did not affect the cardiovascular variables, except that the cardiac output was decreased at 30╩min after the drug administration. Additional administration of 200╩mg/kg of AH-1058 (n=6) suppressed the sinus nodal automaticity, AV nodal conduction and ventricular contraction and decreased the mean blood pressure, cardiac output and double product. The effects gradually appeared, while no change was detected in the intraventricular conduction, ventricular repolarization period, ventricular effective refractory period, preload to the left ventricle and total peripheral vascular resistance during the observation period of 30╩min. The cardiosuppressive effects of AH-1058 can be explained by its calcium channel blocking action demonstrated in a previous in vitro experiment, while the lack of the effect on the vascular resistance would suggest that AH-1058 may become a slow-acting cardioselective calcium channel blocker.

Keywords: AH-1058, Calcium channel blocker, Electrophysiologic effect, Hemodynamic action,
Monophasic action potential


Copyrightę The Japanese Pharmacological Society 2000

[Back to TOC]